U.S. Real Estate Stock News

If you are wondering whether Jabil's current share price reflects its underlying value, this article will walk you through what the numbers actually say. Jabil shares last closed at US$257.40, with returns of a 0.6% decline over 7 days, 2.4% over 30 days, 7.1% year to date, 51.7% over 1 year and a very large gain over 5 years. Recent headlines around Jabil have focused on its position as a key manufacturing partner for large electronics and industrial customers, as well as ongoing portfolio...

Why Banc of California is on investors’ radar today Banc of California (BANC) is drawing attention after recent share price moves, with the stock last closing at $20.10. Investors are weighing this level against the bank’s current earnings profile and valuation signals. See our latest analysis for Banc of California. At the current share price of $20.10, Banc of California’s recent 18.93% 3 month share price return and 29.49% 1 year total shareholder return suggest momentum has improved...

If you are trying to figure out whether Ocular Therapeutix at around US$6.99 still offers value or has run its course, you are in the right place. The stock has recently been volatile, with a 22.6% decline over the last 7 days, a 38.0% decline over 30 days and a 40.9% decline year to date, while the 3 year return sits at 21.8%. Recent headlines around Ocular Therapeutix have focused on its position in ophthalmology and how its pipeline and products could shape future prospects. This helps...

HubSpot, Inc.'s ( NYSE:HUBS ) strong earnings report was rewarded with a positive stock price move. We did some digging...

Anterix Inc.'s ( NASDAQ:ATEX ) stock performed strongly after the recent earnings report. However, we think that...

In the last year, multiple insiders have substantially increased their holdings of aTyr Pharma, Inc. ( NASDAQ:ATYR...

Q2 Holdings, Inc.'s ( NYSE:QTWO ) earnings announcement last week was disappointing for investors, despite the decent...

Some Yum China Holdings, Inc. ( NYSE:YUMC ) shareholders may be a little concerned to see that the CEO & Executive...

Some TTM Technologies, Inc. ( NASDAQ:TTMI ) shareholders may be a little concerned to see that the Director, Thomas...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

AtriCure, Inc. recently reported its fourth quarter and full-year 2025 results, with quarterly revenue of US$140.5 million, a swing to net income of US$1.76 million, and substantially reduced full-year losses alongside 2025 revenue of US$534.53 million. Management also issued 2026 guidance calling for US$600 million to US$610 million in revenue and positive net income, while highlighting progress in key clinical programs and new product launches that could influence the company’s market...

Brookdale Senior Living (BKD) is back in focus as it prepares to release its Q4 2025 earnings after the market closes today, with investors watching revenue trends and loss expectations closely. See our latest analysis for Brookdale Senior Living. The share price has been strong heading into the release, with a 30 day share price return of 36.39% and a year to date share price return of 53.51%. At the same time, the 1 year total shareholder return of 213.96% and 3 year total shareholder...

If you are wondering whether Innodata's recent share price pulls you toward a bargain or a value trap, this article will walk through what the current market price might be saying about the stock. The share price closed at US$43.02, with returns of a 9.5% decline over 7 days, a 30.1% decline over 30 days and an 18.8% decline year to date. Over the past 3 years and 5 years, the returns are very large compared to the starting point. Over the past year, Innodata has also recorded a 25.9%...

Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships. See our latest analysis for Corteva. Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building,...

Palantir Technologies (NasdaqGS:PLTR) is relocating its headquarters from Denver to Miami. The move places Palantir among a group of technology firms expanding operations in Florida. The relocation reflects management’s growing presence in the Miami area and interest in the state’s business environment. Palantir focuses on data analytics and AI platforms used by government agencies and commercial clients, so its corporate moves tend to draw attention from both investors and policymakers...

Kinsale Capital Group, Inc. recently reported past fourth quarter and full-year 2025 results, with revenue rising to US$483.27 million and US$1.87 billion respectively, alongside higher net income and earnings per share year over year. The company’s strong profitability was accompanied by a new US$0.25 per-share dividend declaration and a board transition that reduces the director count from ten to nine without reported governance disputes. We’ll now explore how Kinsale’s stronger earnings...

Pfizer reported positive pivotal results from its BREAKWATER trial for the BRAFTOVI based regimen in first line treatment of BRAF V600E mutant metastatic colorectal cancer. The data showed significant progression free survival improvements, and Pfizer is moving the regimen through the approval process as a potential new therapy option. For investors watching NYSE:PFE, this update adds a fresh data point to the story at a time when the stock trades around $27.37. Shares are up 6.7% over the...

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive long term results from the RELIEVE UCCD extension study of duvakitug in ulcerative colitis and Crohn’s disease. The TL1A antibody maintained efficacy and safety over 44 weeks in patients with inflammatory bowel disease. The partners plan to advance duvakitug into phase III trials, targeting a potential best in class therapy in this treatment area. For you as an investor following NYSE:TEVA, this update sits at the...

Wondering whether Affirm Holdings at around US$51.60 still lines up with the story you have in mind, or if the current price is getting ahead of itself or lagging behind the fundamentals. The stock has recently been volatile, with a 13.5% decline over the last 7 days, a 31.0% decline over the last 30 days, and a 30.3% decline year to date, even though the 3 year return is very large at about 3x and the 1 year return sits at a 36.3% decline. Recent headlines around Affirm have focused on its...

Why recent analyst upgrades are putting BorgWarner (BWA) on investors’ radar Recent analyst upgrades for BorgWarner (BWA), backed by fresh supply deals in electric and hybrid systems, have pushed the stock into focus for investors watching the auto parts shift toward electrified powertrains. See our latest analysis for BorgWarner. BorgWarner’s recent contracts in hybrid and electric systems, a fresh Master Supply Agreement for turbine generators tied to AI data centers, an active buyback...

Garmin (NYSE:GRMN) launched the Catalyst 2 motorsports performance optimizer and the zūmo XT3 GPS device for motorcyclists. The company acquired a large aviation facility at Mesa Gateway airport to expand its aviation footprint. Garmin entered a partnership with Brazos Safety Systems to provide aviation safety analytics. For you as an investor, these moves show how Garmin is leaning into its core segments of motorsports, motorcycling, and aviation with fresh hardware and new operational...

Leggett & Platt (LEG) just released fourth quarter and full year 2025 results alongside 2026 guidance, pairing higher profitability with softer sales and a cautious outlook that gives investors several moving pieces to weigh. See our latest analysis for Leggett & Platt. Leggett & Platt’s latest earnings update lands after a mixed stretch for investors, with a 32.96% 90 day share price return and 18.64% 1 year total shareholder return contrasting with a 60.31% 3 year total shareholder return...

Fabrinet recently reported record second‑quarter fiscal 2026 revenue of US$1.13 billion, reflecting 36% year‑over‑year growth driven by strong demand for its high‑bandwidth optical networking products used in AI‑focused data centers. Institutional investors and analysts have emphasized Fabrinet’s niche role in advanced optical hardware for data centers, suggesting that AI‑related workloads are becoming an increasingly important engine for its manufacturing business. We’ll now examine how...

Pennsylvania jury orders Johnson & Johnson to pay damages in a talc baby powder case related to alleged cancer risks. Verdict arrives as more talc trials are scheduled across the US, with thousands of related lawsuits still pending. US FDA approves a new monthly dosing schedule for RYBREVANT FASPRO as a first line lung cancer treatment. For investors watching Johnson & Johnson (NYSE:JNJ), this mix of legal and drug development news comes with the stock recently trading at about $243.33. The...